Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells

Cancer Immunology, Immunotherapy

Volumn 60, Issue 1, 2011, Pages 49-60

  Warncke, Max ^a   Buchner, Maike ^a   Thaller, Gudrun ^a   Dodero, Anna ^a   Bulashevska, Alla ^a,b   Pfeifer, Dietmar ^a   Timmer, Jens ^b   Veelken, Hendrik ^a,c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

FoxP3; Idiotype; Lymphoma; Regulatory T cell

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; INTERLEUKIN 10; PEPTIDE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CD4+ CD25+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; GENE EXPRESSION PROFILING; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CELL PROLIFERATION; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; GENE EXPRESSION PROFILING; H-2 ANTIGENS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNIZATION; IMMUNOGLOBULIN IDIOTYPES; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGIC SURVEILLANCE; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES, REGULATORY;

EID: 79953741219     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0918-x     Document Type: Article

References (41)

1. Stevenson GT, Elliott EV, Stevenson FK (1977) Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target. Fed Proc 36(9):2268-2271 (Pubitemid 8138672)
2. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL, Kwak LW (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 5(10):1171-1177 (Pubitemid 29474422)
3. Bertinetti C, Zirlik K, Heining-Mikesch K, Ihorst G, Dierbach H, Waller CF, Veelken H (2006) Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Cancer Res 66(8):4496-4502
4. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2(1):52-58 (Pubitemid 26028073)
5. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 89(9):3129-3135
6. Inoges S, Rodriguez-Calvillo M, Zabalegui N, Lopez-Diaz de Cerio A, Villanueva H, Soria E, Suarez L, Rodriguez-Caballero A, Pastor F, Garcia-Munoz R, Panizo C, Perez-Calvo J, Melero I, Rocha E, Orfao A, Bendandi M (2006) Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 98(18):1292-1301 (Pubitemid 44530725)
7. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R (2004) Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin g fc receptor genotype. J Clin Oncol 22(23):4717-4724
8. Levy R, Robertson M, Leonard J, Vose J, Denney D (2008) Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular nonhodgkin's lymphoma (fNHL). Ann Oncol 19(Suppl 4):iv101
9. Lauritzsen GF, Weiss S, Dembic Z, Bogen B (1994) Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci USA 91(12):5700-5704 (Pubitemid 24174396)
10. Kwak LW, Young HA, Pennington RW, Weeks SD (1996) Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 93(20):10972-10977 (Pubitemid 26333102)
11. Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW (1996) Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 156(10):3858-3865
12. Bogen B, Ruffini P (2009) Review: to what extent are T cells tolerant to immunoglobulin variable regions? Scand J Immunol 70(6):526-530
13. Osterroth F, Garbe A, Fisch P, Veelken H (2000) Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells. Blood 95(4):1342-1349 (Pubitemid 30099845)
14. Strothmeyer AM, Papaioannou D, Duhren-von Minden M, Navarrete M, Zirlik K, Heining-Mikesch K, Veelken H (2010) Comparative analysis of predicted HLA binding of immunoglobulin idiotype sequences indicates T-cell-mediated immunosurveillance in follicular lymphoma. Blood 116(10):1734-1736
15. Baskar S, Kobrin CB, Kwak LW (2004) Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. J Clin Invest 113(10):1498-1510 (Pubitemid 39071706)
16. Navarrete MA, Heining-Mikesch K, Bertinetti-Lapatki C, Duehren-von Minden M, Hafkemeyer A, Veelken H (2008) Vaccination with recombinant idiotype Fab fragments induces specific cellular immunity and clinical responses in untreated B-cell lymphoma patients. Blood 112(11):235
17. Tamura M, Kuwano K, Kurane I, Ennis FA (1998) Definition of amino acid residues on the epitope responsible for recognition by influenza a virus H1-specific, H2-specific, and H1- and H2-cross-reactive murine cytotoxic T-lymphocyte clones. J Virol 72(11):9404-9406 (Pubitemid 28471897)
18. Warncke M, Dodero A, Dierbach H, Follo M, Veelken H (2006) Murine dendritic cells generated under serum-free conditions have a mature phenotype and efficiently induce primary immune responses. J Immunol Methods 310(1-2):1-11 (Pubitemid 43375970)
19. Morgan DJ, Liblau R, Scott B, Fleck S, McDevitt HO, Sarvetnick N, Lo D, Sherman LA (1996) Cd8(+) T cell-mediated spontaneous diabetes in neonatal mice. J Immunol 157(3):978-983
20. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203(7):1701-1711 (Pubitemid 44036276)
21. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4(2):249-264
22. Baldi P, Long AD (2001) A bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics 17(6):509-519 (Pubitemid 32600497)
23. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 57:289-300
24. Pannetier C, Cochet M, Darche S, Casrouge A, Zoller M, Kourilsky P (1993) The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA 90(9):4319-4323 (Pubitemid 23134218)
25. Doenecke A, Winnacker EL, Hallek M (1997) Rapid amplification of cDNA ends (race) improves the PCR-based isolation of immunoglobulin variable region genes from murine and human lymphoma cells and cell lines. Leukemia 11(10):1787-1792 (Pubitemid 27458620)
26. Armstrong AC, Dermime S, Allinson CG, Bhattacharyya T, Mulryan K, Gonzalez KR, Stern PL, Hawkins RE (2002) Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J Immunol 168(8):3983-3991 (Pubitemid 34298403)
27. Dyall R, Bowne WB, Weber LW, LeMaoult J, Szabo P, Moroi Y, Piskun G, Lewis JJ, Houghton AN, Nikolic-Zugic J (1998) Heteroclitic immunization induces tumor immunity. J Exp Med 188(9):1553-1561 (Pubitemid 28516100)
28. Hill JA, Feuerer M, Tash K, Haxhinasto S, Perez J, Melamed R, Mathis D, Benoist C (2007) FoxP3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity 27(5):786-800 (Pubitemid 350110546)
29. Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, Rudensky AY (2007) Genome-wide analysis of FoxP3 target genes in developing and mature regulatory T cells. Nature 445(7130):936-940
30. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG (1997) A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389(6652):737-742 (Pubitemid 27458961)
31. Yamaguchi T, Hirota K, Nagahama K, Ohkawa K, Takahashi T, Nomura T, Sakaguchi S (2007) Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 27(1):145-159 (Pubitemid 47089022)
32. Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133(5):775-787 (Pubitemid 351707693)
33. Rudensky AY, Campbell DJ (2006) In vivo sites and cellular mechanisms of T reg cell-mediated suppression. J Exp Med 203(3):489-492
34. Apostolou I, Sarukhan A, Klein L, von Boehmer H (2002) Origin of regulatory T cells with known specificity for antigen. Nat Immunol 3(8):756-763
35. Zhou G, Drake CG, Levitsky HI (2006) Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107(2):628-636 (Pubitemid 43076387)
36. Sarris M, Andersen KG, Randow F, Mayr L, Betz AG (2008) Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 28(3):402-413
37. Lim HW, Broxmeyer HE, Kim CH (2006) Regulation of traf- ficking receptor expression in human forkhead box P3+ regulatory T cells. J Immunol 177(2):840-851 (Pubitemid 44036584)
38. Marski M, Kandula S, Turner JR, Abraham C (2005) CD18 is required for optimal development and function of CD4+ CD25+ T regulatory cells. J Immunol 175(12):7889-7897 (Pubitemid 41798349)
39. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS (2003) CD4+ CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9(9):1144-1150 (Pubitemid 37173698)
40. Mempel TR, Pittet MJ, Khazaie K, Weninger W, Weissleder R, von Boehmer H, von Andrian UH (2006) Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 25(1):129-141 (Pubitemid 44066829)
41. Trojan A, Schultze JL, Witzens M, Vonderheide RH, Ladetto M, Donovan JW, Gribben JG (2000) Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 6(6):667-672 (Pubitemid 30398790)